IDEAYA Biosciences Enters Material Definitive Agreement
Ticker: IDYA · Form: 8-K · Filed: Dec 30, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.045 b, $75 million, $200 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing-update
TL;DR
IDEAYA inked a new deal on Dec 27th, 8-K filed.
AI Summary
On December 27, 2024, IDEAYA Biosciences, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.
Why It Matters
This filing indicates a significant new agreement for IDEAYA Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to terms, obligations, and potential future performance.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- December 27, 2024 (date) — Date of earliest event reported
- South San Francisco, California (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the nature of the material definitive agreement entered into by IDEAYA Biosciences?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 27, 2024.
When was the report filed with the SEC?
The report was filed on December 30, 2024.
What is IDEAYA Biosciences' standard industrial classification?
IDEAYA Biosciences, Inc. falls under the Pharmaceutical Preparations [2834] standard industrial classification.
Where are IDEAYA Biosciences' principal executive offices located?
IDEAYA Biosciences, Inc.'s principal executive offices are located at 5000 Shoreline Court, Suite 300, South San Francisco, California 94080.
What is the fiscal year end for IDEAYA Biosciences?
IDEAYA Biosciences, Inc.'s fiscal year ends on December 31.
Filing Stats: 691 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-12-30 06:04:51
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
- $1.045 b — upfront and milestone payments totaling $1.045 billion, including a $75 million upfront
- $75 million — ts totaling $1.045 billion, including a $75 million upfront fee, up to $200 million in deve
- $200 million — luding a $75 million upfront fee, up to $200 million in development and regulatory milestone
Filing Documents
- d917390d8k.htm (8-K) — 27KB
- d917390dex991.htm (EX-99.1) — 14KB
- 0001193125-24-286169.txt ( ) — 165KB
- idya-20241227.xsd (EX-101.SCH) — 3KB
- idya-20241227_lab.xml (EX-101.LAB) — 18KB
- idya-20241227_pre.xml (EX-101.PRE) — 11KB
- d917390d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 29, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: December 30, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer